FY2026 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate to a loss of $3.79 per share from a projected loss of $3.98, and forecasts losses narrowing in 2027–28 before turning profitable in 2029. It maintained a Buy rating and a $65 price target.
  • uniQure’s latest quarter showed an EPS loss of $0.88, better than the $0.92 loss analysts expected, while revenue of $5.2 million fell short of the $6.17 million consensus estimate.
  • Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $55.58.
  • Five stocks to consider instead of uniQure.

uniQure N.V. (NASDAQ:QURE - Free Report) - Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of uniQure in a research note issued on Wednesday, November 18th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of ($3.79) for the year, up from their prior forecast of ($3.98). HC Wainwright currently has a "Buy" rating and a $65.00 price target on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.83) per share. HC Wainwright also issued estimates for uniQure's Q4 2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.88) EPS, Q2 2027 earnings at ($0.92) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.70) EPS, FY2027 earnings at ($3.31) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at $1.48 EPS and FY2030 earnings at $3.87 EPS.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. The business had revenue of $5.20 million during the quarter, compared to the consensus estimate of $6.17 million.

Other equities research analysts have also recently issued research reports about the company. The Goldman Sachs Group dropped their target price on uniQure from $46.00 to $31.00 and set a "neutral" rating on the stock in a report on Wednesday, September 30th. Wolfe Research raised shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a report on Wednesday, July 29th. UBS Group initiated coverage on shares of uniQure in a research note on Thursday, October 15th. They set a "buy" rating and a $48.00 target price for the company. Weiss Ratings upgraded shares of uniQure from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, September 21st. Finally, Barclays cut uniQure from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $60.00 to $28.00 in a report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, uniQure presently has an average rating of "Moderate Buy" and an average price target of $55.58.

Check Out Our Latest Analysis on QURE

uniQure Stock Performance

QURE stock opened at $20.23 on Friday. The company has a quick ratio of 11.52, a current ratio of 11.52 and a debt-to-equity ratio of 0.17. The company has a 50-day simple moving average of $27.55 and a 200 day simple moving average of $29.62. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $51.72.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of QURE. Seven Fleet Capital Management LP bought a new stake in shares of uniQure in the 2nd quarter valued at approximately $15,254. IFP Advisors Inc raised its holdings in uniQure by 18.0% during the third quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company's stock valued at $79,000 after buying an additional 500 shares in the last quarter. Arizona State Retirement System lifted its position in shares of uniQure by 17.7% in the second quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company's stock worth $596,000 after buying an additional 1,942 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of uniQure during the 3rd quarter valued at about $86,000. Finally, Rangeley Capital LLC lifted its holdings in uniQure by 52.9% in the 1st quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company's stock worth $213,000 after purchasing an additional 4,500 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

Trending Headlines about uniQure

Here are a few of the latest headlines about QURE:

  • Positive Sentiment: HC Wainwright raised its 2026 and 2027 EPS forecasts, projecting smaller losses, and also narrowed its estimated 2028 loss. It retained a Buy rating, which may support sentiment around the company’s outlook.
  • Neutral Sentiment: HC Wainwright’s $65 price target remains above the current share price, but it was reduced from $80. A separate report puts the average analyst target at $56.83. Article: uniQure Stock Has Average Price Target of $56.83
  • Negative Sentiment: The lower $65 target is a downgrade to HC Wainwright’s valuation outlook. The firm also cut its projected EPS for 2029 and 2030, tempering the positive revisions to nearer-term estimates. Article: uniQure Price Target Cut by HC Wainwright

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients' cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington's disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

Featured Stories

Earnings History and Estimates for uniQure (NASDAQ:QURE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in uniQure Right Now?

Before you consider uniQure, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.

While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines